A crosslinked polymer skin barrier film for moderate to severe atopic dermatitis: A pilot study in adults.
atopic dermatitis
eczema
inflammatory skin diseases
itch
silicone dressing
skin barrier function
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
21
05
2019
revised:
05
09
2019
accepted:
09
09
2019
pubmed:
8
10
2019
medline:
11
11
2020
entrez:
8
10
2019
Statut:
ppublish
Résumé
Occlusive treatments are a mainstay in atopic dermatitis (AD) management but may not be well tolerated or lack compliance. A comfortable, semiocclusive, artificial skin barrier that is well tolerated, provides protection, and reduces water loss is needed. To evaluate the potential tolerability and therapeutic benefits of a crosslinked polymer layer (XPL) in adults with AD. A single-center, open-label pilot study was conducted involving 10 subjects with moderate to severe AD. Subjects applied XPL up to twice daily for 30 days on a selected treatment area. Investigator's Global Assessment, clinical signs of eczema, and pruritus were assessed on days 1, 3, 5, 15, and 30. Film durability and patient satisfaction were also evaluated. Investigator's Global Assessment scores improved from moderate to severe at baseline to clear to almost clear in 8 of 9 patients at day 30. Pruritus improved from trace to severe itching (baseline) to all subjects having trace to no itching at day 30. There was 1 adverse event of mild exudative dermatitis. The study was limited by small sample size, open-label design, and lack of control. XPL may be an effective adjuvant in AD treatment. A larger study with a control group is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Occlusive treatments are a mainstay in atopic dermatitis (AD) management but may not be well tolerated or lack compliance. A comfortable, semiocclusive, artificial skin barrier that is well tolerated, provides protection, and reduces water loss is needed.
OBJECTIVE
OBJECTIVE
To evaluate the potential tolerability and therapeutic benefits of a crosslinked polymer layer (XPL) in adults with AD.
METHODS
METHODS
A single-center, open-label pilot study was conducted involving 10 subjects with moderate to severe AD. Subjects applied XPL up to twice daily for 30 days on a selected treatment area. Investigator's Global Assessment, clinical signs of eczema, and pruritus were assessed on days 1, 3, 5, 15, and 30. Film durability and patient satisfaction were also evaluated.
RESULTS
RESULTS
Investigator's Global Assessment scores improved from moderate to severe at baseline to clear to almost clear in 8 of 9 patients at day 30. Pruritus improved from trace to severe itching (baseline) to all subjects having trace to no itching at day 30. There was 1 adverse event of mild exudative dermatitis.
LIMITATIONS
CONCLUSIONS
The study was limited by small sample size, open-label design, and lack of control.
CONCLUSION
CONCLUSIONS
XPL may be an effective adjuvant in AD treatment. A larger study with a control group is warranted.
Identifiants
pubmed: 31589946
pii: S0190-9622(19)32822-1
doi: 10.1016/j.jaad.2019.09.073
pii:
doi:
Substances chimiques
Cross-Linking Reagents
0
Polymers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
895-901Informations de copyright
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.